Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Kyoto scientists reveal characteristic behaviors of erythropoietin-producing cells

A research team at Kyoto University has revealed characteristic behaviors of erythropoietin (Epo)-producing cells.

30 Jun 2022

Researchers explore disease severity post-infection with SARS-CoV-2 Omicron in hematologic patients

A new study has studied the clinical outcome and spectrum in 61 patients infected with the SARS-CoV-2 Omicron variant.

29 Jun 2022

The effect on newborns’ health from marijuana use during pregnancy

Researchers assessed the impact of marijuana use on neonatal outcomes.

10 Jun 2022

Oral pill taken once a day improves outcomes of patients with myelofibrosis

Momelotinib, an oral pill taken once a day, significantly improved outcomes of patients treated for myelofibrosis (MF), a rare but fatal bone marrow cancer, researchers reported June 7.

7 Jun 2022

Nectar of common plants could be used to help fight Leishmania infections

The nectar of common plants such as sunflower contain bioactive agents that can inhibit the growth of Leishmania and could be used to help fight the potentially fatal disease caused by the parasite, say researchers.

2 Jun 2022

Study finds TGF-β2 associated with asymptomatic mild SARS-CoV-2 infection during pregnancy

A new study investigated the clinical and obstetric outcomes after SARS-CoV-2 infection in two groups of pregnant women, along with their association with the immunological parameters.

28 May 2022

Serological biomarker predicts severe Crohn's disease seven years prior to diagnosis

An international team led by a University of Toronto researcher has found that an antibody detectable in blood predicts severe Crohn's disease and is detectable up to seven years prior to disease diagnosis.

24 May 2022

New, minimally invasive biomarker-based strategy 90% successful in detecting esophageal cancer

In a small but rigorous pilot study, Johns Hopkins Medicine researchers have shown that a novel, minimally invasive biomarker-based strategy they developed was 90% successful in detecting esophageal squamous cell carcinoma (ESCC), the predominant subtype of esophageal cancer worldwide.

18 May 2022

Cannabidiol for Parkinson's disease symptom management

Scientists have published a review study in the Journal for Nurse Practitioners that has focussed on various aspects of the use of cannabidiol in Parkinson's.

17 May 2022

Is type 1 diabetes likely to rise after the COVID pandemic?

A recent article posted to the journal Diabetes/Metabolism Research and Reviews explored the risk of a type 1 diabetes wave after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.

6 May 2022

UrFU researchers propose the use of polyoxometallate nanoclusters as chemotherapy drug carrier

Researchers at Ural Federal University have proposed the use of polyoxometallate nanoclusters as a carrier for chemotherapy drug. It will help to deliver medications precisely to the focus of a pathological process, such as a cancerous tumor, without toxic effects on healthy cells.

28 Apr 2022

World Malaria Day 2022: How the knockdown of P. falciparum RAP01 and RAP21 proteins could lead to novel antimalarial therapeutics

As part of World Malaria Day 2022, we interview Karine Le Roch PH.D., about her latest research into how novel antimalarial therapeutic strategies could be on the horizon, after identifying two proteins that are critical to the survival of the malaria parasite, Plasmodium falciparum.

25 Apr 2022

Efficacy of vaccination against SARS-CoV-2 Omicron BA.1 and BA.2 sublineages in Sweden

Researchers compared the vaccine effectiveness against infections by SARS-CoV-2 variant of concern Omicron BA.1 and BA.2 sublineages in Sweden.

22 Apr 2022

Texas A&M AgriLife scientists receive grant to fight pesticide-resistant cattle fever ticks

Two projects by Texas A&M AgriLife Research scientists aim to protect the U.S. cattle industry from the emerging threat of pesticide-resistant cattle fever ticks.

21 Apr 2022

New therapeutic option for HPV-positive head and neck carcinoma discovered

The various manifestations of head and neck carcinomas rank sixth in frequency worldwide and are fatal for about half a million people every year. In a quarter of cases, head and neck squamous cell carcinoma (HNSCC) is caused by human papillomavirus (HPV) and, currently, is not always treatable.

19 Apr 2022

New short-course treatment effective against HIV-associated cryptococcal meningitis

A new short-course treatment is effective against HIV-associated cryptococcal meningitis with fewer serious side effects, and has the potential to reduce the length and cost of hospital admissions, a study shows.

15 Apr 2022

COVID-19 may affect a group of biochemical reactions called one-carbon metabolism

A new study addresses the relationship between SARS-CoV-2 to the metabolism of one-carbon molecules in the host, suggesting new therapeutic pathways.

13 Apr 2022

Therapies for LGL leukemia should target the immune system, not only cancer cells

An international study coordinated by a University of Helsinki research group demonstrates that the body's immune system attacks itself in a rare type of blood cancer.

11 Apr 2022

Drugs targeting DNA damage response pathway show therapeutic potential against advanced solid tumors

Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers -; ATR inhibitor elimusertib and PARP inhibitor AZD5305 -; are safe and clinically beneficial in treating patients with advanced solid tumors.